Flow Cytometric Immune Profiling Enables Early Detection of Rejection in Islet Xenotransplantation
Xenotransplantation · 2026-09 · 33 (5)
DOI: 10.1111/xen.70170 ↗Abstract
ABSTRACT Background Islet xenotransplantation is a strategy for treatment of Type 1 Diabetes, but immune‐mediated rejection limits graft survival. This study investigated a strategy with flow cytometry–based immune monitoring to evaluate immunosuppressive therapy and provide indicators of graft rejection. Methods Porcine neonatal islet cell clusters (NICC) from GTKO‐hCD55‐hCD59 transgenic pigs were transplanted into streptozotocin‐induced diabetic baboons ( n = 10). Recipients received anti‐CD2 induction with anti‐CD154, Belatacept, and full‐dose ( n = 7) or reduced/no dose Tacrolimus ( n = 3). Leukocyte subsets and activation status were monitored using multiplex flow cytometry. Graft function was assessed by blood glucose measurements, porcine C‐peptide ELISA, and histological analysis. Results Porcine C‐peptide was detected in all recipients. Seven animals receiving full‐dose Tacrolimus maintained NICC function for up to 675 days, whereas three experienced acute rejection within two months. Flow cytometry generated absolute leukocyte counts equivalent to standard full blood counts (Deming regression slope 0.91–1.03, p
EUVIMED